U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Post-Warning Letter Meetings Under GDUFA
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Post-Warning Letter Meetings Under GDUFA June 2025

Final Level 1 Guidance
Docket Number:
FDA-2023-D-3370
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research
Office of Inspections and Investigations

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Post-Warning Letter Meetings Under GDUFA.” This guidance provides information on the implementation of the Post-Warning Letter Meeting process for certain drug manufacturing facilities, a program enhancement agreed upon by the Agency and industry as part of the negotiations relating to the reauthorization of the Generic Drug User Fee Amendments (GDUFA), as described in “GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023--2027” (GDUFA III commitment letter). Specifically, this guidance describes the process detailed in the GDUFA III commitment letter for how an eligible facility may request a Post-Warning Letter Meeting with FDA regarding the facility’s ongoing remediation efforts to address current good manufacturing practice (CGMP) deficiencies described in a warning letter, how to prepare and submit a complete meeting package, and how FDA intends to conduct the Post-Warning Letter Meeting.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2023-D-3370.

Back to Top